Aerpio Pharmaceuticals, Inc

(NASDAQ:ARPO)

Latest On Aerpio Pharmaceuticals, Inc (ARPO):

Date/Time Type Description Signal Details
2021-08-27 04:39 ESTNewsAadi Bioscience closes merger with Aerpio Pharmaceuticals and $155M private placementN/A
2021-07-31 05:09 ESTNewsAerpio Pharmaceuticals: Is This Stock A Buy Or Sell? Not Until The Merger Is OverN/A
2021-07-20 19:32 ESTNewsTalkspace and 9 Meters initiated as outperform, and Cantor bullish on COMPASS in today's analyst actionN/A
2021-03-12 07:09 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 03:09 ESTEarnings EstimateAn EPS average of -$0.12 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-12 03:09 ESTEarnings EstimateAn EPS average of -$0.39 is estimated for the 2022 year.Sell
2021-03-11 23:43 ESTNewsAerpio Pharms EPS beats by $0.04N/A
2021-03-05 15:15 ESTNewsQuantum halts testing Aerpio Pharmaceuticals' razuprotafib in COVID-19 settingN/A
2021-01-06 02:53 ESTNewsAerpio launches process to explore strategic alternativesN/A
2020-12-15 03:13 ESTAnalyst RatingThe Analyst Target Price has decreased from $3 to $1.75.Neutral
2020-12-13 03:14 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 19:21 ESTNewsAerpio announces results from Razuprotafib Glaucoma Phase 2 TrialN/A
2020-12-10 03:13 ESTAnalyst RatingThe Analyst Target Price has increased from $2 to $3.Buy
2020-12-06 16:41 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-22 16:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 11:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 19:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 12:49 ESTNewsAerpio Pharms EPS beats by $0.02N/A
2020-11-11 12:48 ESTNewsAerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-11 11:09 ESTEarnings EstimateAn EPS average of -$0.14 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-01 17:06 ESTFinancialsCompany financials have been released.Neutral
2020-10-27 14:37 ESTNewsMid-stage study of Aerpio's razuprotafib for COVID-19 underwayN/A
2020-09-26 04:18 ESTFinancialsCompany financials have been released.Neutral
2020-09-16 13:09 ESTNewsAerpio concludes enrollment in mid-stage study of razuprotafib in glaucomaN/A
2020-09-02 07:44 ESTNewsMid-stage platform study underway assessing treatments for critically ill COVID-19 patientsN/A
2020-08-14 16:08 ESTAnalyst RatingThe Analyst Target Price has increased from $1 to $2.Buy
2020-08-14 16:08 ESTEarnings EstimateAn EPS average of -$0.63 is estimated for the 2021 year.Sell
2020-08-14 08:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 11:50 ESTNewsAerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-12 09:55 ESTNewsAerpio Pharms EPS misses by $0.04, revenue in-lineN/A
2020-08-06 10:55 ESTNewsAerpio Pharma up big on funding of razuprotafib study in COVID-19N/A
2020-07-31 00:12 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 12:09 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:17 ESTFinancialsCompany financials have been released.Neutral
2020-06-25 05:44 ESTNewsAerpio launches mid-stage study of razuprotafib in glaucomaN/A
2020-06-04 18:41 ESTInsider TradeJoseph H. Gardner has directly acquired 5,000 shares and currently holds 448,019 shares.Buy
2020-06-04 18:41 ESTInsider TradeJoseph H. Gardner has directly acquired 5,000 shares and currently holds 453,019 shares.Buy
2020-05-31 16:35 ESTFinancialsCompany financials have been released.Neutral
2020-05-28 09:43 ESTNewsAerpio Pharma up on planned study of razuprotafib in COVID-19N/A
2020-05-10 00:10 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 07:41 ESTNewsAerpio Pharms EPS misses by $0.01N/A
2020-05-03 08:10 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 02:24 ESTNewsAerpio Pharms EPS beats by $0.01N/A
2020-04-07 00:11 ESTFinancialsCompany financials have been released.Neutral
2020-03-26 00:07 ESTFinancialsCompany financials have been released.Neutral
2020-03-19 00:08 ESTFinancialsCompany financials have been released.Neutral
2020-03-17 04:08 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on June 30, 2020.Sell
2020-03-16 21:41 ESTNewsAerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call TranscriptN/A

About Aerpio Pharmaceuticals, Inc (ARPO):

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

ARPO Quotes by TradingView

See Advanced Chart

General

  • Name Aerpio Pharmaceuticals, Inc
  • Symbol ARPO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 12
  • Fiscal Year EndDecember
  • IPO Date2017-08-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.aerpio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 4.72
  • Price/Book (Most Recent Quarter) 1.82
  • Enterprise Value Revenue 2.4
  • Enterprise Value EBITDA 0.24
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.33
  • Next Year EPS Estimate -$0.39
  • Next Quarter EPS Estimate -$0.11
  • Profit Margin -29%
  • Operating Margin -42%
  • Return on Assets -9%
  • Return on Equity -11%
  • Revenue 15 million
  • Earnings Per Share -$0.28
  • Revenue Per Share $0.35
  • Gross Profit 15 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 79.01 million
  • EBITDA -11516735
  • Analyst Target Price $1.75
  • Book Value Per Share $0.91
View More

Share Statistics

  • Shares Outstanding 47.31 million
  • Shares Float 40.8 million
  • % Held by Insiders 1618%
  • % Held by Institutions 41.53%
  • Shares Short 518712
  • Shares Short Prior Month 1.35 million
  • Short Ratio 0.21
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.82
  • 52 Week High $2.29
  • 52 Week Low $0.45
  • 50 Day Moving Average 1.71
  • 200 Day Moving Average 1.46
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aerpio Pharmaceuticals, Inc (ARPO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aerpio Pharmaceuticals, Inc (ARPO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.11-$0.1418.52%
2020-09-302020-11-10$N/A-$0.12-$0.1414.29%
2020-06-302020-08-12$15 million$0.23$0.27-14.81%
2020-03-312020-05-07$N/A-$0.10-$0.09-11.11%
2019-12-312020-03-16$N/A-$0.09-$0.1229.17%
2019-09-302019-11-07$N/A-$0.12-$0.1414.44%
2019-06-302019-08-08$N/A-$0.12-$0.1730.88%
2019-03-312019-05-09$N/A-$0.21-$0.224.55%
2018-12-312019-03-05$2144-$0.21-$0.236.67%
2018-09-302018-11-07$18.82 million$0.28$0.29-2.34%
2018-06-302018-08-14$1.33 million-$0.22-$0.232.22%
2018-03-312018-05-15$N/A-$0.27-$0.23-17.39%
2017-12-312018-03-13$N/A-$0.23-$0.23-0.52%
2017-09-302017-11-29$N/A-$0.17

Aerpio Pharmaceuticals, Inc (ARPO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.23 million N/A 3.55 million N/A 2.13 million
Income Before Tax -4.72 million N/A 9.28 million N/A -4.45 million
Selling General Administrative 2.41 million N/A 2.2 million N/A 1.54 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -4.72 million N/A 9.27 million N/A -3.67 million
Operating Income -5.64 million N/A 9.26 million N/A -3.67 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A 15 million N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -776000
Net Income From Continuing Operations -4.72 million N/A 9.28 million N/A -4.45 million
Net Income Applicable to Common Shares -4.72 million -4.96 million 9.28 million -3.92 million -4.45 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -6827 -12198 N/A N/A N/A
Change to Liabilities N/A N/A -675858 N/A 1155
Total Cash Flow from Investing Activities N/A N/A N/A N/A -4281
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities N/A N/A 249779 N/A -782439
Change in Cash 2.42 million 10.28 million N/A N/A -4.77 million
Total Cash from Operating Activities -6.92 million 10.29 million -3.94 million N/A -4.76 million
Depreciation 15718 15067 N/A N/A 20189
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A 389814 N/A 645899
Capital Expenditures 6827 N/A N/A N/A 4281
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 1.87 million N/A 3.12 million N/A 3.4 million
Total Stockholder Equity 43.06 million N/A 42.6 million N/A 36.54 million
Other Current Liabilities 67438 N/A N/A N/A N/A
Total Assets 44.92 million N/A 45.72 million N/A 39.94 million
Common Stock 4725 189.15 million 179.48 million 4059 178.77 million
Other Current Assets 2.11 million 1.85 million 263081 N/A 735000
Retained Earnings -146.55 million -141.83 million -136.88 million -146.15 million -142.24 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A 20000 20000 20000 40000
Cash 42.6 million N/A 44.86 million N/A 38.53 million
Total Current Liabilities 1.87 million 2.51 million 3.11 million N/A 3.34 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 121730 227000 261000 287905 326000
Total Current Assets 44.72 million 49.58 million 45.43 million N/A 39.57 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 43.06 million 47.32 million 42.6 million 33.01 million 36.54 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.8 million 2.42 million 622658 N/A 3.23 million

Aerpio Pharmaceuticals, Inc (ARPO) Chart:

Aerpio Pharmaceuticals, Inc (ARPO) News:

Below you will find a list of latest news for Aerpio Pharmaceuticals, Inc (ARPO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aerpio Pharmaceuticals, Inc (ARPO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Aerpio Pharmaceuticals, Inc (ARPO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017777/0000899243-20-017777-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319013769/0000899243-19-013769-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017437/0000899243-19-017437-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017438/0000899243-19-017438-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017439/0000899243-19-017439-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017440/0000899243-19-017440-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017441/0000899243-19-017441-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017443/0000899243-19-017443-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319017445/0000899243-19-017445-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319019320/0000899243-19-019320-index.htm
2019-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319019449/0000899243-19-019449-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319025919/0000899243-19-025919-index.htm
2019-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924319026769/0000899243-19-026769-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320008921/0000899243-20-008921-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320008922/0000899243-20-008922-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320008925/0000899243-20-008925-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017769/0000899243-20-017769-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017774/0000899243-20-017774-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017775/0000899243-20-017775-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017776/0000899243-20-017776-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1422142/000089924320017777/0000899243-20-017777-index.htm
2019-06-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1422142/000110465919034544/0001104659-19-034544-index.htm
2020-04-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1422142/000110465920049516/0001104659-20-049516-index.htm
2020-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1422142/000110465920061960/0001104659-20-061960-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519176575/0001193125-19-176575-index.htm
2019-07-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519204117/0001193125-19-204117-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519216013/0001193125-19-216013-index.htm
2019-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519265750/0001193125-19-265750-index.htm
2019-10-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519270159/0001193125-19-270159-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312519286608/0001193125-19-286608-index.htm
2020-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520003545/0001193125-20-003545-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520014836/0001193125-20-014836-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520073937/0001193125-20-073937-index.htm
2020-03-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1422142/000119312520074970/0001193125-20-074970-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520135674/0001193125-20-135674-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520140527/0001193125-20-140527-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520153860/0001193125-20-153860-index.htm
2020-06-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1422142/000119312520163583/0001193125-20-163583-index.htm
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520178434/0001193125-20-178434-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520209863/0001193125-20-209863-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1422142/000119312520209872/0001193125-20-209872-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1422142/000119312520217056/0001193125-20-217056-index.htm
2020-09-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1422142/000119312520254584/0001193125-20-254584-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1422142/000156459019030747/0001564590-19-030747-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1422142/000156459019041774/0001564590-19-041774-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1422142/000156459020011174/0001564590-20-011174-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1422142/000156459020017281/0001564590-20-017281-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1422142/000156459020018861/0001564590-20-018861-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1422142/000156459020018874/0001564590-20-018874-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1422142/000156459020022411/0001564590-20-022411-index.htm
2020-05-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1422142/000156459020023616/0001564590-20-023616-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1422142/000156459020039505/0001564590-20-039505-index.htm
2020-03-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1422142/000156761920005890/0001567619-20-005890-index.htm

Aerpio Pharmaceuticals, Inc (ARPO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aerpio Pharmaceuticals, Inc (ARPO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1618%
Institutional Ownership: 4153%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-07-03Joseph H. GardnerPresidentBuy5,000.000.904,485.00448,019.00https://www.sec.gov/Archives/edgar/data/1422142/000089924319019320/0000899243-19-019320-index.htm
2019-07-10Joseph H. GardnerPresidentBuy5,000.000.814,073.50453,019.00https://www.sec.gov/Archives/edgar/data/1422142/000089924319019449/0000899243-19-019449-index.htm